Diversified biotechnology company CCM Biosciences (CCM Bio) announced the launch of its business unit CCM 5Prime Sciences (5Prime) focused on the development and application of proprietary technology in the domain of DNA biotechnology. 5Prime’s technology platform includes multiple patent-protected, globally commercialized compositions and methods for molecular cloning, next-generation DNA sequencing and molecular diagnostics.

Enable Biosciences said on Tuesday that it has received a $3 million Phase IIB Small Business Innovation Research grant from the National Institute of Diabetes and Digestive and Kidney Diseases for its type 1 diabetes test.

QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, has received 510(K) clearance from the U.S. Food and Drug Administration for its innovative Savanna PCR platform and Savanna HSV 1+2/VZV in vitro diagnostic test for the detection and differentiation of Herpes simplex virus type 1 (HSV-1), Herpes simplex virus type 2 (HSV-2) and Varicella-zoster virus (VZV) nucleic acids isolated and purified from swabs obtained from cutaneous or mucocutaneous lesion specimens obtained from symptomatic patients.

Euroimmun, a Revvity company, and Xpedite Diagnostics have partnered to offer DNA extraction protocols for point-of-care diagnostics.

Geneoscopy and Adiso Therapeutics announced on Tuesday a strategic collaboration that will involve the use of Geneoscopy's stool-based transcriptome platform to assess patient response to Adiso's experimental treatment for inflammatory bowel disease (IBD).

Revvity said on Monday it has received a CE-IVD mark for a molecular testing platform that can be used to screen newborns for spinal muscular atrophy and severe combined immunodeficiency.

Roche announced on Tuesday that its Cobas HPV test has received approval from the US Food and Drug Administration for use on the Cobas 5800 instrument.

Co-Diagnostics has received an $8.97m grant from the Bill & Melinda Gates Foundation to support a tuberculosis (TB) test that is under development.

An international team of researchers has developed a PCR-based assay to detect mitochondrial DNA (mtDNA) damage in blood, an indicator of Parkinson's disease. The test may help diagnose the condition before the nervous system of patients is excessively damaged, they said, and could be used to measure response to certain drugs in development to treat the disease.

ChromaCode on Thursday announced a partnership with cancer diagnostic laboratory Protean BioDiagnostics to launch a test for non-small cell lung cancer through an early access program.